JP2002508326A - インテグリン受容体拮抗薬 - Google Patents

インテグリン受容体拮抗薬

Info

Publication number
JP2002508326A
JP2002508326A JP2000538696A JP2000538696A JP2002508326A JP 2002508326 A JP2002508326 A JP 2002508326A JP 2000538696 A JP2000538696 A JP 2000538696A JP 2000538696 A JP2000538696 A JP 2000538696A JP 2002508326 A JP2002508326 A JP 2002508326A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
amino
aminocarbonyl
aminosulfonylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000538696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002508326A5 (https=
Inventor
ダガン，マーク・イー
パーキンス，ジエイムス・ジエイ
マイスナー，ロバート・エス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807384.4A external-priority patent/GB9807384D0/en
Priority claimed from GBGB9815803.3A external-priority patent/GB9815803D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2002508326A publication Critical patent/JP2002508326A/ja
Publication of JP2002508326A5 publication Critical patent/JP2002508326A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2000538696A 1997-12-17 1998-12-14 インテグリン受容体拮抗薬 Withdrawn JP2002508326A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US6990997P 1997-12-17 1997-12-17
GBGB9807384.4A GB9807384D0 (en) 1998-04-06 1998-04-06 Vitronectin receptor antagonists
GB9807384.4 1998-04-06
US8325098P 1998-04-27 1998-04-27
US9263098P 1998-07-13 1998-07-13
GB60/069,909 1998-07-21
GB60/092,630 1998-07-21
GB60/083,250 1998-07-21
GB9815803.3 1998-07-21
GBGB9815803.3A GB9815803D0 (en) 1998-07-21 1998-07-21 Vitronectin receptor antagonists
PCT/US1998/026485 WO1999030713A1 (en) 1997-12-17 1998-12-14 Integrin receptor antagonists

Publications (2)

Publication Number Publication Date
JP2002508326A true JP2002508326A (ja) 2002-03-19
JP2002508326A5 JP2002508326A5 (https=) 2006-02-02

Family

ID=27517454

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000538696A Withdrawn JP2002508326A (ja) 1997-12-17 1998-12-14 インテグリン受容体拮抗薬

Country Status (8)

Country Link
EP (1) EP1044001B1 (https=)
JP (1) JP2002508326A (https=)
AT (1) ATE299023T1 (https=)
AU (1) AU738452B2 (https=)
CA (1) CA2315232A1 (https=)
DE (1) DE69830806T2 (https=)
ES (1) ES2243015T3 (https=)
WO (1) WO1999030713A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005539049A (ja) * 2002-08-16 2005-12-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ インテグリンと選択的に結合するピペリジニル化合物

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU747784B2 (en) * 1998-07-29 2002-05-23 Merck & Co., Inc. Integrin receptor antagonists
WO2000009503A1 (en) * 1998-08-13 2000-02-24 Merck & Co., Inc. Integrin receptor antagonists
EP1156803A4 (en) 1999-02-09 2004-03-17 Bristol Myers Squibb Co FXA LACTAM INHIBITORS AND METHOD
TR200102944T2 (tr) 1999-04-13 2002-08-21 Basf Aktiengesellschaft İntegrin reseptör ligandları
PT1187592E (pt) 1999-06-02 2007-10-19 Merck & Co Inc Antagonistas dos receptores de integrina alfa v
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
EP1229910A4 (en) 1999-10-04 2003-10-01 Merck & Co Inc integrin
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
CA2397194C (en) 2000-01-20 2011-05-17 Mark E. Duggan Alpha v integrin receptor antagonists
JP2004511434A (ja) 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
AU2001292598B2 (en) 2000-09-14 2006-06-29 Merck & Co., Inc. Alpha V integrin receptor antagonists
NZ539682A (en) 2001-01-29 2006-03-31 Dimensional Pharm Inc Substituted indoles and their use as integrin antagonists
WO2002085405A2 (en) 2001-04-24 2002-10-31 Merck Patent Gmbh COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
EP1572690A1 (en) 2002-12-20 2005-09-14 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2007207465B2 (en) 2006-01-18 2012-12-06 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
CN101588812A (zh) 2007-01-18 2009-11-25 默克专利有限公司 使用整联蛋白配体治疗癌的特异疗法和药物
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
PL3050878T3 (pl) 2013-09-24 2022-01-24 Fujifilm Corporation Zawierający atom azotu związek lub jego sól, lub ich kompleks z metalem
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
MA47697A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'(alpha-v)(bêta-6) intégrine
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
EP4086254B1 (en) 2018-08-29 2024-12-18 Morphic Therapeutic, Inc. Integrin inhibitors
FI3844162T3 (fi) 2018-08-29 2025-03-27 Morphic Therapeutic Inc Alfa v beeta6 -integriinin estäjiä
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
EP4541422A3 (en) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929618A (en) * 1988-03-25 1990-05-29 Ube Industries, Ltd. Piperdine and piperazine derivatives, and antihistaminic pharmaceutical compositions containing the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005539049A (ja) * 2002-08-16 2005-12-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ インテグリンと選択的に結合するピペリジニル化合物

Also Published As

Publication number Publication date
DE69830806D1 (de) 2005-08-11
DE69830806T2 (de) 2006-04-27
EP1044001A1 (en) 2000-10-18
ATE299023T1 (de) 2005-07-15
EP1044001B1 (en) 2005-07-06
CA2315232A1 (en) 1999-06-24
EP1044001A4 (en) 2003-01-29
AU738452B2 (en) 2001-09-20
ES2243015T3 (es) 2005-11-16
AU1912899A (en) 1999-07-05
WO1999030713A1 (en) 1999-06-24

Similar Documents

Publication Publication Date Title
JP2002508326A (ja) インテグリン受容体拮抗薬
JP3585839B2 (ja) インテグリン受容体拮抗薬
JP2002522540A (ja) インテグリン受容体拮抗薬
JP3589633B2 (ja) インテグリン受容体拮抗薬
US6040311A (en) Integrin receptor antagonists
US6066648A (en) Integrin receptor antagonists
JP3808707B2 (ja) αｖインテグリン受容体拮抗薬
US6413955B1 (en) Integrin receptor antagonists
JP4787447B2 (ja) αｖインテグリン受容体拮抗薬
JP2002508323A (ja) インテグリン受容体拮抗薬
JP2002536370A (ja) α−Ｖインテグリン受容体拮抗薬としてのベンゾアゼピン誘導体
JP2001504456A (ja) インテグリン拮抗薬
US6358970B1 (en) Integrin receptor antagonists
JP2001509176A (ja) インテグリンアンタゴニスト
US5952341A (en) Integrin antagonists
JP2001503060A (ja) インテグリン拮抗薬
JP2002511052A (ja) インテグリンアンタゴニスト
JP2003520271A (ja) αｖインテグリン受容体拮抗薬
JP2004509123A (ja) アルファνインテグリン受容体アンタゴニスト
JP2004504349A (ja) αｖインテグリン受容体拮抗薬
US6211184B1 (en) Integrin antagonists
US6211191B1 (en) Integrin receptor antagonists
JP2002537260A (ja) αＶインテグリン受容体拮抗薬としてのジベンゾ−アゼピン誘導体
US6916810B2 (en) αν integrin receptor antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051207

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060119